[go: up one dir, main page]

DK3345618T3 - Middel til forbedring af immunitet over for cancer ved hjælp af allergin-1-antagonist - Google Patents

Middel til forbedring af immunitet over for cancer ved hjælp af allergin-1-antagonist Download PDF

Info

Publication number
DK3345618T3
DK3345618T3 DK16842026.3T DK16842026T DK3345618T3 DK 3345618 T3 DK3345618 T3 DK 3345618T3 DK 16842026 T DK16842026 T DK 16842026T DK 3345618 T3 DK3345618 T3 DK 3345618T3
Authority
DK
Denmark
Prior art keywords
allergin
antagonist
measure
immunity against
against cancer
Prior art date
Application number
DK16842026.3T
Other languages
English (en)
Inventor
Shiro Shibayama
Hiroshi Arima
Takuya Simbo
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of DK3345618T3 publication Critical patent/DK3345618T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276Knock-out vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/12Animals modified by administration of exogenous cells
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK16842026.3T 2015-09-03 2016-09-02 Middel til forbedring af immunitet over for cancer ved hjælp af allergin-1-antagonist DK3345618T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015173659 2015-09-03
JP2016138374 2016-07-13
PCT/JP2016/075887 WO2017038997A1 (ja) 2015-09-03 2016-09-02 Allergin-1アンタゴニストによるがん免疫増強剤

Publications (1)

Publication Number Publication Date
DK3345618T3 true DK3345618T3 (da) 2022-02-07

Family

ID=58189017

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16842026.3T DK3345618T3 (da) 2015-09-03 2016-09-02 Middel til forbedring af immunitet over for cancer ved hjælp af allergin-1-antagonist

Country Status (22)

Country Link
US (2) US11638744B2 (da)
EP (1) EP3345618B1 (da)
JP (2) JP6156604B1 (da)
KR (1) KR102611244B1 (da)
CN (1) CN108025069B (da)
AU (1) AU2016317378B2 (da)
CA (1) CA2997240C (da)
DK (1) DK3345618T3 (da)
ES (1) ES2905554T3 (da)
HU (1) HUE058293T2 (da)
IL (1) IL257773B (da)
MX (1) MX394957B (da)
MY (1) MY197664A (da)
NZ (1) NZ740351A (da)
PH (1) PH12018500450A1 (da)
PL (1) PL3345618T3 (da)
PT (1) PT3345618T (da)
RU (1) RU2734777C2 (da)
SG (1) SG11201801699VA (da)
TW (1) TWI765862B (da)
WO (1) WO2017038997A1 (da)
ZA (1) ZA201801471B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
TW202408578A (zh) * 2016-05-13 2024-03-01 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
WO2023123337A1 (en) * 2021-12-31 2023-07-06 Dalian University Of Technology Leukemia-related marker and use thereof
KR20250052397A (ko) 2022-08-23 2025-04-18 오노 야꾸힝 고교 가부시키가이샤 이중 특이성 항체

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69317883T2 (de) * 1992-11-17 1998-11-12 Icos Corp., Bothell, Wash. Neue Sieben-Transmembran-Rezeptor V28
US20030232411A1 (en) 1997-12-26 2003-12-18 Ono Pharmaceutical Co., Ltd. Novel polypeptide, cDNA encoding the same, and use thereof
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US6872548B2 (en) * 2001-01-31 2005-03-29 Human Genome Sciences, Inc. Scaffolded fusion polypeptides and compositions and methods for making the same
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
EP1640452A4 (en) * 2003-05-30 2009-12-23 Nippon Shinyaku Co Ltd OLIGOBICATENARY RNA INHIBITING BCL-2 EXPRESSION AND MEDICINAL COMPOSITION CONTAINING THE SAME
JP5272310B2 (ja) 2004-10-21 2013-08-28 小野薬品工業株式会社 免疫抑制受容体の用途
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) * 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
US20090306349A1 (en) * 2006-03-31 2009-12-10 Rampak Corp Binding partners with immunoglobulin domains modified to have extended half-life
WO2007122815A1 (ja) 2006-04-14 2007-11-01 Ono Pharmaceutical Co., Ltd. Bir1に対する二価抗体
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
CA2696591C (en) 2007-08-20 2016-10-11 Oncotherapy Science, Inc. Cdh3 peptide and medicinal agent comprising the same
EP2331130B1 (en) * 2008-04-09 2018-02-14 Oncoquest Inc. Ige antibodies for the treatment of cancer
KR101258456B1 (ko) 2011-01-13 2013-04-26 강원대학교산학협력단 백혈구의 혈관외유출 억제 활성 및 비만세포 탈과립 억제 활성을 갖는 펩타이드를 포함하는 약학 조성물
US9381210B2 (en) * 2013-04-15 2016-07-05 Wisconsin Alumni Research Foundation Induced pluripotent stem cell model of chronic myeloid leukemia revealed olfactomedin 4 as a novel therapeutic target in leukemia stem cells
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
JP6901400B2 (ja) * 2015-04-03 2021-07-14 ゾーマ テクノロジー リミテッド TGF−β及びPD−1の阻害物質を使用する癌の治療法

Also Published As

Publication number Publication date
ZA201801471B (en) 2019-06-26
US20180244771A1 (en) 2018-08-30
US20230256054A1 (en) 2023-08-17
EP3345618B1 (en) 2022-01-05
ES2905554T3 (es) 2022-04-11
CN108025069A (zh) 2018-05-11
JPWO2017038997A1 (ja) 2017-08-31
EP3345618A1 (en) 2018-07-11
JP6750559B2 (ja) 2020-09-02
CN108025069B (zh) 2021-11-12
TWI765862B (zh) 2022-06-01
RU2734777C2 (ru) 2020-10-23
TW201712035A (zh) 2017-04-01
MX394957B (es) 2025-03-24
CA2997240C (en) 2024-04-02
NZ740351A (en) 2022-10-28
US11638744B2 (en) 2023-05-02
KR102611244B1 (ko) 2023-12-06
WO2017038997A1 (ja) 2017-03-09
PT3345618T (pt) 2022-02-02
MX2018002681A (es) 2018-04-13
AU2016317378B2 (en) 2021-11-11
RU2018107687A3 (da) 2020-02-21
MY197664A (en) 2023-06-30
KR20180041687A (ko) 2018-04-24
JP6156604B1 (ja) 2017-07-05
CA2997240A1 (en) 2017-03-09
RU2018107687A (ru) 2019-10-03
EP3345618A4 (en) 2019-03-13
IL257773A (en) 2018-04-30
HUE058293T2 (hu) 2022-07-28
SG11201801699VA (en) 2018-04-27
PH12018500450A1 (en) 2018-09-10
AU2016317378A1 (en) 2018-03-29
PL3345618T3 (pl) 2022-03-28
JP2018016619A (ja) 2018-02-01
IL257773B (en) 2021-08-31

Similar Documents

Publication Publication Date Title
CL2016002502A1 (es) Inhibidores de biaril cinasa
EP3369061A4 (en) INTERFACES FOR SECURE TRANSACTIONS
LT3157916T (lt) Heteroarilo junginiai, skirti kinazės inhibavimui
LT3197883T (lt) Nauji junginiai
DK3132034T3 (da) Terapeutikum
DK3072835T3 (da) Fremgangsmåde til fremføring
PT3298027T (pt) Compostos depsipéptidos antelmínticos
DK3204359T3 (da) Tetrahydroisoquinolinderivater
FR3028873B1 (fr) Installation de fractionnement
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
DK3186244T3 (da) Dioxolananaloger af uridin til behandling af cancer
EP3183255C0 (en) SPIROPYRROLIDINES USEFUL AS MDM2 INHIBITORS
HUE069651T2 (hu) Farmakofór TRAIL indukcióra
LT3233813T (lt) Į oksatiaziną panašių junginių gavimo būdai
DK3212637T3 (da) Dopamin-d3-receptorantagonistforbindelser
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
DK3296597T3 (da) Krydshovedmotor
LT3362444T (lt) Junginiai
EP3140315C0 (en) NEW CATH2 DERIVATIVES
PT3131898T (pt) Derivados de fluoroalquilfluoreno
DK3320226T3 (da) Bøjle med hurtigudløsning
DK3597189T3 (da) Krystallinske forbindelser
HUE039805T2 (hu) Új szulfonilaminobenzamid vegyületek
EP3868751C0 (en) 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS